SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB Biotherapeutics Inc., formerly known as Big Cypress Acquisition Corp., is based in SIOUX FALLS, S.D.
Revenue (Most Recent Fiscal Year) | $2.24M |
Net Income (Most Recent Fiscal Year) | $-42.19M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 10.14 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.50 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -1531.26% |
Net Margin (Trailing 12 Months) | -1531.26% |
Return on Equity (Trailing 12 Months) | -109.90% |
Return on Assets (Trailing 12 Months) | -72.78% |
Current Ratio (Most Recent Fiscal Quarter) | 5.65 |
Quick Ratio (Most Recent Fiscal Quarter) | 5.65 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.06 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $6.21 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.54 |
Earnings per Share (Most Recent Fiscal Year) | $-7.64 |
Diluted Earnings per Share (Trailing 12 Months) | -- |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 9.23M |
Free Float | 6.79M |
Market Capitalization | $26.40M |
Average Volume (Last 20 Days) | 7368.05 |
Beta (Past 60 Months) | 0.68 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 26.46% |
Percentage Held By Institutions (Latest 13F Reports) | 7.82% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |